Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
etodolac + cyclobenzaprine
- Development stage
- Unknown
- Lead developer
- Apsen Farmacêutica
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Etodolac + cyclobenzaprine is an oral fixed-dose combination of two small-molecule drugs: **etodolac**, a nonsteroidal anti-inflammatory drug (NSAID) that acts as a cyclooxygenase (COX) inhibitor to reduce pain and inflammation, and **cyclobenzaprine**, a centrally acting skeletal muscle relaxant structurally related to tricyclic antidepressants, which works primarily via antagonism of serotonin 5-HT2A receptors, histamine H1 receptors, and alpha 1 adrenergic receptors to alleviate muscle spasms and pain. This combination is being developed to treat pain, especially postoperative pain, in adults and elderly patients. The drug has undergone phase III clinical development, but at least one phase III study was terminated due to recruitment difficulty[3].
- Other names
- cyclobenzaprine/etodolac
02
Targets
HTR2A (Serotonin receptor 5-HT2A)PTGS2 (Prostaglandin-Endoperoxide Synthase 2)HRH1 (Histamine H1 Receptor)ADRA1A (α1A)PGHS-1 (Prostaglandin G/H Synthase 1)
Beyond the preview
Go deeper on etodolac + cyclobenzaprine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on etodolac + cyclobenzaprine.